2016/01/01 by Raymond M. Fertig, Jerry Shapiro, Wilma F. Bergfeld +1 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Hormonal and reproductive studies #Sexual function and dysfunction studies #Sexual Differentiation and Disorders #Finasteride #Gynecomastia #Decreased Libido #Libido #Medicine #Discontinuation #Erectile dysfunction #Dutasteride #Sexual dysfunction #Anxiety #5 Alpha-Reductase Inhibitor #Internal medicine #Psychiatry #Prostate cancer
paper · pdf · doi:10.1159/000450617
openalex publication_date 2016/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
Postfinasteride syndrome (PFS) is a term recently coined to characterize a constellation of reported undesirable side effects described in postmarketing reports and small uncontrolled studies that developed during or after stopping finasteride treatment, and persisted after drug discontinuation. Symptoms included decreased libido, erectile dysfunction, sexual anhedonia, decreased sperm count, gynecomastia, skin changes, cognitive impairment, fatigue, anxiety, depression, and suicidal ideation. The aim of this study is to review the existing medical literature for evidence-based research of permanent sexual dysfunction and mood changes during treatment with 5-alpha-reductase inhibitors including finasteride and dutasteride.